Immunotherapy biomarkers in neoadjuvant breast cancer
Predictive biomarkers for response to checkpoint inhibitors in TNBCПодробнее
Using gut microbiota to enhance immunotherapy for breast cancerПодробнее
Utilizing neoadjuvant immunotherapies in patients with ER+, HER2- primary breast cancerПодробнее
Educational Sessions: "Immunotherapy in the metastatic setting - chemo backbone and biomarker"Подробнее
NeoALTTO: HER2/CEP17 ratio as a predictive biomarker in HER+ breast cancerПодробнее
I-SPY2.2: emerging biomarkers in breast cancerПодробнее
STS Webinar: Biomarker Testing and Neoadjuvant Immunotherapy for Resectable NSCLCПодробнее
The role of immune biomarkers in guiding breast cancer treatment decisionsПодробнее
TNBC: immunotherapy in the neoadjuvant settingПодробнее
Refining Best Practices in Cancer Immunotherapy Biomarker Testing and Pathologic Response AssessmentПодробнее
Expert report on treatment with Tumour-Infiltrating Lymphocytes (TILs)Подробнее
Gaining Confidence in Predicting and Assessing Response to Cancer ImmunotherapiesПодробнее
Chemotherapy, Immunotherapy, Targeted therapy for gastric cancer, esophageal cancer -Edusurg ClinicsПодробнее
MPCCC Cancer Seminars: A/Prof Yoland AntillПодробнее
Pathologic Response After Neoadjuvant Immunotherapy: Facilitating Progress in Early-Stage CancersПодробнее
Strategies to improve the response to immunotherapy in TNBCПодробнее
Prognostic biomarkers of immunotherapy efficacy in breast cancerПодробнее
Testing, Treating, and Targeting Triple Negative Breast Cancer | 2023 West Oncology ConferenceПодробнее
Tumor infiltrating lymphocytes (TILs) as a predictive biomarker in breast cancerПодробнее